We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+7.15%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.94B
AUM Growth
-$464M
Cap. Flow
-$553M
Cap. Flow %
-18.83%
Top 10 Hldgs %
35.63%
Holding
94
New
11
Increased
10
Reduced
24
Closed
23

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$66.6M
2
JNJ icon
Johnson & Johnson
JNJ
+$53.2M
3
IRTC icon
iRhythm Holdings
IRTC
+$48.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.4M
5
CAH icon
Cardinal Health
CAH
+$31.4M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$57.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$51.2M
3
HCA icon
HCA Healthcare
HCA
+$47.7M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$43.2M
5
GILD icon
Gilead Sciences
GILD
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.07%
2 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
51
Praxis Precision Medicines
PRAX
$8.52B
$12.5M 0.43%
42,394
+12,036
+40% +$3.53M
BFLY icon
52
Butterfly Network
BFLY
$2.35B
$12.2M 0.42%
1,828,311
– –
ADAP
53
DELISTED
Adaptimmune Therapeutics
ADAP
$12M 0.41%
3,201,066
-1,202,508
-27% -$5.47M
INCY icon
54
Incyte
INCY
$24B
$9.5M 0.32%
+129,428
New +$8.73M
OSH
55
DELISTED
Oak Street Health, Inc.
OSH
$9.26M 0.32%
+279,357
New +$10.6M
IOBT
56
DELISTED
IO Biotech
IOBT
$7.74M 0.26%
+1,362,144
New +$13.2M
AERI
57
DELISTED
Aerie Pharmaceuticals
AERI
$7.64M 0.26%
1,088,566
-1,094,118
-50% -$11.4M
LUNG icon
58
Pulmonx
LUNG
$89.5M
$6.71M 0.23%
209,193
+72,617
+53% +$2.65M
PMVP icon
59
PMV Pharmaceuticals
PMVP
$59.7M
$6.66M 0.23%
288,334
– –
PRDS
60
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$5.92M 0.2%
361,528
-638,472
-64% -$7.43M
GILD icon
61
Gilead Sciences
GILD
$163B
$5.59M 0.19%
76,993
-589,608
-88% -$40.6M
HOWL icon
62
Werewolf Therapeutics
HOWL
$17.9M
$4.76M 0.16%
400,000
– –
KNTE
63
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$4.68M 0.16%
264,293
– –
BLSA
64
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.55M 0.15%
464,103
– –
JYAC
65
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.53M 0.15%
464,103
– –
LAB icon
66
Standard BioTools
LAB
$339M
$3.84M 0.13%
980,505
– –
DXCM icon
67
DexCom
DXCM
$32.9B
$2.4M 0.08%
17,876
-52,164
-74% -$7.5M
PRCT icon
68
Procept Biorobotics
PRCT
$1.04B
$1.63M 0.06%
65,000
– –
ALNA
69
DELISTED
Allena Pharmaceuticals
ALNA
$168K 0.01%
284,285
– –
ADAP
70
CALL
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-291,800
Closed -$1.51M
ALLO icon
71
Allogene Therapeutics
ALLO
$635M
– –
-775,819
Closed -$19.9M
AVIR icon
72
Atea Pharmaceuticals
AVIR
$369M
– –
-302,532
Closed -$10.6M
BIIB icon
73
Biogen
BIIB
$29.8B
– –
-16,900
Closed -$4.78M
BMY icon
74
CALL
Bristol-Myers Squibb
BMY
$135B
– –
-612,000
Closed -$36.2M
BYSI icon
75
BeyondSpring
BYSI
$48.1M
– –
-161,697
Closed -$2.55M
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q4 2021 Portfolio in Review

As of Q4 2021, PFM Health Sciences held 94 positions worth $2.94B, down 14% from $3.4B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $553M in Q4 2021, closing 23 positions and reducing 24 holdings. Its most notable exit was Allogene Therapeutics, an estimated $19.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 86% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Pfizer worth $79.3M.

  • PFM Health Sciences's largest Q4 2021 buy was Pfizer: 1,343,384 shares worth $79.3M.
  • PFM Health Sciences added most to CATALENT, INC. in Q4 2021, an estimated $19.1M increase.
  • PFM Health Sciences's biggest Q4 2021 reduction was Eli Lilly, cutting an estimated $57.5M.
  • PFM Health Sciences fully exited Allogene Therapeutics in Q4 2021, selling an estimated $19.9M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $2.94B portfolio in Q4 2021.
  • PFM Health Sciences opened 11 new positions and closed 23 in Q4 2021.
  • PFM Health Sciences's portfolio value fell 14% quarter-over-quarter to $2.94B.

Based on PFM Health Sciences's 13F filing for Q4 2021, filed 14 Feb 2022.